Characteristics of the Patients with Confirmed or Highly Suspected COVID-19 and IBD
| . | Total (n = 83) . | Ambulatory (n = 78) . | Hospitalized (n = 5) . |
|---|---|---|---|
| Demographics | |||
| Age (median, IQR) | 35 (27–45) | 35 (27–44) | 49 (25–76) |
| Sex | |||
| Male | 44 (53%) | 40 (51%) | 4 (80%) |
| Female | 39 (47%) | 38 (49%) | 1 (20%) |
| Race | |||
| White | 58 (70%) | 54 (70%) | 4 (80%) |
| Black | 5 (6%) | 5 (6%) | 0 |
| Asian | 3 (4%) | 3 (4%) | 0 |
| Other | 17 (20%) | 16 (21%) | 1 (20%) |
| Ethnicity | |||
| Hispanic | 9 (11%) | 7 (9%) | 2 (40%) |
| Non-Hispanic | 74 (89%) | 71 (91%) | 3 (60%) |
| Comorbidities | |||
| Organ transplantation | 2 (2%) | 2 (3%) | 0 |
| Kidney disease | 1 (2%) | 1 (1%) | 0 |
| Pregnancy | 4 (5%) | 3 (4%) | 1 (20%) |
| Current malignancy | 1 (2%) | 0 | 1 (20%) |
| Hypertension | 3 (4%) | 3 (4%) | 0 |
| Diabetes mellitus | 1 (2%) | 1 (1%) | 0 |
| COPD | 1 (2%) | 1 (1%) | 0 |
| Asthma | 9 (11%) | 9 (12%) | 0 |
| ACE inhibitor/ARB use | 6 (7%) | 5 (6%) | 1 (20%) |
| IBD Characteristics | |||
| IBD subtype | |||
| Crohn’s disease | 56 (67%) | 52 (67%) | 4 (80%) |
| Ulcerative colitis | 27 (33%) | 26 (33%) | 1 (20%) |
| IBD disease status by physician assessment | |||
| Remission | 30 (36%) | 30 (38%) | 0 |
| Mild | 26 (31%) | 24 (31%) | 2 (40%) |
| Moderate | 14 (17%) | 13 (17%) | 1 (20%) |
| Severe | 6 (7%) | 4 (5%) | 2 (40%) |
| Unknown | 7 (8%) | 7 (9%) | 0 |
| IBD medication use | |||
| None | 4 (5%) | 3 (4%) | 1 (20%) |
| 5-ASA | 13 (16%) | 11 (14%) | 1 (20%) |
| Immunomodulators | 6 (7%) | 5 (6%) | 1 (20%) |
| Azathioprine/Mercaptopurine | 2 (2%) | 2 (3%) | 0 |
| Methotrexate | 4 (5%) | 3 (4%) | 1 (20%) |
| Corticosteroids | 10 (12%) | 8 (10%) | 1 (20%) |
| Prednisone | 6 (6%) | 4 (5%) | 1 (20%) |
| >20 mg/daily | 5 (4%) | 3 (4%) | 1 (20%) |
| Oral budesonide | 4 (6%) | 4 (5%) | 0 |
| Biologics | 58 (70%) | 56 (71%) | 2 (40%) |
| Vedolizumab | 5 (6%) | 5 (6%) | 0 |
| Anti-TNF | 44 (53%) | 42 (53%) | 2 (40%) |
| Infliximab | 23 (28%) | 23 (29%) | 0 |
| Adalimumab | 21 (25%) | 19 (24%) | 2 (40%) |
| Ustekinumab | 9 (11%) | 9 (11%) | 0 |
| Tofacitinib | 4 (5%) | 4 (5%) | 0 |
| COVID-19 Characteristics | |||
| COVID-19 symptoms | |||
| Fever >99 F | 55 (66%) | 52 (66%) | 3 (60%) |
| Cough | 46 (55%) | 44 (56%) | 2 (20%) |
| Pharyngitis | 21 (25%) | 21 (27%) | 0 |
| Rhinorrhea | 15 (18%) | 15 (19%) | 0 |
| Diarrhea | 26 (31%) | 24 (30%) | 2 (40%) |
| Ageusia | 18 (22%) | 18 (23%) | 0 |
| Anosmia | 25 (30%) | 25 (32%) | 0 |
| Shortness of breath | 21 (25%) | 17 (22%) | 4 (80%) |
| Days of symptoms (median, IQR) | 11 (5–15) | 11 (6–15) | 17 (9–32) |
| Positive SARS-CoV-2 testing | 45 (54%) | 40 (51%) | 5 (100%) |
| Highly suspected COVID-19 | 38 (46%) | 39 (49%) | 0 |
| Level of care | |||
| Notified provider | 28 (34%) | 28 (36%) | - |
| Outpatient provider visit | 48 (58%) | 48 (61%) | - |
| Severe outcomes | 7 (8%) | 2 (3%) | 5 (100%) |
| ER only | 2 (2%) | 2 (3%) | - |
| Hospitalized | 5 (6%) | - | 5 (100%) |
| ICU with intubation | 1 (1%) | - | 1 (20%) |
| IBD medication management | |||
| Continued | 58 (70%) | 57 (72%) | 1 (20%) |
| Held | 13 (16%) | 10 (13%) | 3 (60%) |
| Reduced dose/frequency | 7 (8%) | 7 (9%) | 0 |
| After reduction, required holding | 3 (4%) | 3 (4%) | 0 |
| Medical therapies for COVID-19 | |||
| None | 75 (90%) | 74 (94%) | 2 (40%) |
| Any COVID-19 therapy | 8 (10%) | 5 (6%) | 3 (60%) |
| Hydroxycholorquine + Azithromycin | 4 (5%) | 2 (3%) | 2 (40%) |
| Hydroxycholorquine | 2 (2%) | 2 (3%) | 0 |
| Azithromycin | 1 (1%) | 1 (1%) | 0 |
| Hydroxycholorquine + Azithromycin + Tocilizumab | 1 (1%) | 0 | 1 (20%) |
| Death | 1 (2%) | 0 | 1 (20%) |
| Days of follow-up (median, range) | 52 (11–72) | 52 (13–72) | 47 (11–55) |
| . | Total (n = 83) . | Ambulatory (n = 78) . | Hospitalized (n = 5) . |
|---|---|---|---|
| Demographics | |||
| Age (median, IQR) | 35 (27–45) | 35 (27–44) | 49 (25–76) |
| Sex | |||
| Male | 44 (53%) | 40 (51%) | 4 (80%) |
| Female | 39 (47%) | 38 (49%) | 1 (20%) |
| Race | |||
| White | 58 (70%) | 54 (70%) | 4 (80%) |
| Black | 5 (6%) | 5 (6%) | 0 |
| Asian | 3 (4%) | 3 (4%) | 0 |
| Other | 17 (20%) | 16 (21%) | 1 (20%) |
| Ethnicity | |||
| Hispanic | 9 (11%) | 7 (9%) | 2 (40%) |
| Non-Hispanic | 74 (89%) | 71 (91%) | 3 (60%) |
| Comorbidities | |||
| Organ transplantation | 2 (2%) | 2 (3%) | 0 |
| Kidney disease | 1 (2%) | 1 (1%) | 0 |
| Pregnancy | 4 (5%) | 3 (4%) | 1 (20%) |
| Current malignancy | 1 (2%) | 0 | 1 (20%) |
| Hypertension | 3 (4%) | 3 (4%) | 0 |
| Diabetes mellitus | 1 (2%) | 1 (1%) | 0 |
| COPD | 1 (2%) | 1 (1%) | 0 |
| Asthma | 9 (11%) | 9 (12%) | 0 |
| ACE inhibitor/ARB use | 6 (7%) | 5 (6%) | 1 (20%) |
| IBD Characteristics | |||
| IBD subtype | |||
| Crohn’s disease | 56 (67%) | 52 (67%) | 4 (80%) |
| Ulcerative colitis | 27 (33%) | 26 (33%) | 1 (20%) |
| IBD disease status by physician assessment | |||
| Remission | 30 (36%) | 30 (38%) | 0 |
| Mild | 26 (31%) | 24 (31%) | 2 (40%) |
| Moderate | 14 (17%) | 13 (17%) | 1 (20%) |
| Severe | 6 (7%) | 4 (5%) | 2 (40%) |
| Unknown | 7 (8%) | 7 (9%) | 0 |
| IBD medication use | |||
| None | 4 (5%) | 3 (4%) | 1 (20%) |
| 5-ASA | 13 (16%) | 11 (14%) | 1 (20%) |
| Immunomodulators | 6 (7%) | 5 (6%) | 1 (20%) |
| Azathioprine/Mercaptopurine | 2 (2%) | 2 (3%) | 0 |
| Methotrexate | 4 (5%) | 3 (4%) | 1 (20%) |
| Corticosteroids | 10 (12%) | 8 (10%) | 1 (20%) |
| Prednisone | 6 (6%) | 4 (5%) | 1 (20%) |
| >20 mg/daily | 5 (4%) | 3 (4%) | 1 (20%) |
| Oral budesonide | 4 (6%) | 4 (5%) | 0 |
| Biologics | 58 (70%) | 56 (71%) | 2 (40%) |
| Vedolizumab | 5 (6%) | 5 (6%) | 0 |
| Anti-TNF | 44 (53%) | 42 (53%) | 2 (40%) |
| Infliximab | 23 (28%) | 23 (29%) | 0 |
| Adalimumab | 21 (25%) | 19 (24%) | 2 (40%) |
| Ustekinumab | 9 (11%) | 9 (11%) | 0 |
| Tofacitinib | 4 (5%) | 4 (5%) | 0 |
| COVID-19 Characteristics | |||
| COVID-19 symptoms | |||
| Fever >99 F | 55 (66%) | 52 (66%) | 3 (60%) |
| Cough | 46 (55%) | 44 (56%) | 2 (20%) |
| Pharyngitis | 21 (25%) | 21 (27%) | 0 |
| Rhinorrhea | 15 (18%) | 15 (19%) | 0 |
| Diarrhea | 26 (31%) | 24 (30%) | 2 (40%) |
| Ageusia | 18 (22%) | 18 (23%) | 0 |
| Anosmia | 25 (30%) | 25 (32%) | 0 |
| Shortness of breath | 21 (25%) | 17 (22%) | 4 (80%) |
| Days of symptoms (median, IQR) | 11 (5–15) | 11 (6–15) | 17 (9–32) |
| Positive SARS-CoV-2 testing | 45 (54%) | 40 (51%) | 5 (100%) |
| Highly suspected COVID-19 | 38 (46%) | 39 (49%) | 0 |
| Level of care | |||
| Notified provider | 28 (34%) | 28 (36%) | - |
| Outpatient provider visit | 48 (58%) | 48 (61%) | - |
| Severe outcomes | 7 (8%) | 2 (3%) | 5 (100%) |
| ER only | 2 (2%) | 2 (3%) | - |
| Hospitalized | 5 (6%) | - | 5 (100%) |
| ICU with intubation | 1 (1%) | - | 1 (20%) |
| IBD medication management | |||
| Continued | 58 (70%) | 57 (72%) | 1 (20%) |
| Held | 13 (16%) | 10 (13%) | 3 (60%) |
| Reduced dose/frequency | 7 (8%) | 7 (9%) | 0 |
| After reduction, required holding | 3 (4%) | 3 (4%) | 0 |
| Medical therapies for COVID-19 | |||
| None | 75 (90%) | 74 (94%) | 2 (40%) |
| Any COVID-19 therapy | 8 (10%) | 5 (6%) | 3 (60%) |
| Hydroxycholorquine + Azithromycin | 4 (5%) | 2 (3%) | 2 (40%) |
| Hydroxycholorquine | 2 (2%) | 2 (3%) | 0 |
| Azithromycin | 1 (1%) | 1 (1%) | 0 |
| Hydroxycholorquine + Azithromycin + Tocilizumab | 1 (1%) | 0 | 1 (20%) |
| Death | 1 (2%) | 0 | 1 (20%) |
| Days of follow-up (median, range) | 52 (11–72) | 52 (13–72) | 47 (11–55) |
Characteristics of the Patients with Confirmed or Highly Suspected COVID-19 and IBD
| . | Total (n = 83) . | Ambulatory (n = 78) . | Hospitalized (n = 5) . |
|---|---|---|---|
| Demographics | |||
| Age (median, IQR) | 35 (27–45) | 35 (27–44) | 49 (25–76) |
| Sex | |||
| Male | 44 (53%) | 40 (51%) | 4 (80%) |
| Female | 39 (47%) | 38 (49%) | 1 (20%) |
| Race | |||
| White | 58 (70%) | 54 (70%) | 4 (80%) |
| Black | 5 (6%) | 5 (6%) | 0 |
| Asian | 3 (4%) | 3 (4%) | 0 |
| Other | 17 (20%) | 16 (21%) | 1 (20%) |
| Ethnicity | |||
| Hispanic | 9 (11%) | 7 (9%) | 2 (40%) |
| Non-Hispanic | 74 (89%) | 71 (91%) | 3 (60%) |
| Comorbidities | |||
| Organ transplantation | 2 (2%) | 2 (3%) | 0 |
| Kidney disease | 1 (2%) | 1 (1%) | 0 |
| Pregnancy | 4 (5%) | 3 (4%) | 1 (20%) |
| Current malignancy | 1 (2%) | 0 | 1 (20%) |
| Hypertension | 3 (4%) | 3 (4%) | 0 |
| Diabetes mellitus | 1 (2%) | 1 (1%) | 0 |
| COPD | 1 (2%) | 1 (1%) | 0 |
| Asthma | 9 (11%) | 9 (12%) | 0 |
| ACE inhibitor/ARB use | 6 (7%) | 5 (6%) | 1 (20%) |
| IBD Characteristics | |||
| IBD subtype | |||
| Crohn’s disease | 56 (67%) | 52 (67%) | 4 (80%) |
| Ulcerative colitis | 27 (33%) | 26 (33%) | 1 (20%) |
| IBD disease status by physician assessment | |||
| Remission | 30 (36%) | 30 (38%) | 0 |
| Mild | 26 (31%) | 24 (31%) | 2 (40%) |
| Moderate | 14 (17%) | 13 (17%) | 1 (20%) |
| Severe | 6 (7%) | 4 (5%) | 2 (40%) |
| Unknown | 7 (8%) | 7 (9%) | 0 |
| IBD medication use | |||
| None | 4 (5%) | 3 (4%) | 1 (20%) |
| 5-ASA | 13 (16%) | 11 (14%) | 1 (20%) |
| Immunomodulators | 6 (7%) | 5 (6%) | 1 (20%) |
| Azathioprine/Mercaptopurine | 2 (2%) | 2 (3%) | 0 |
| Methotrexate | 4 (5%) | 3 (4%) | 1 (20%) |
| Corticosteroids | 10 (12%) | 8 (10%) | 1 (20%) |
| Prednisone | 6 (6%) | 4 (5%) | 1 (20%) |
| >20 mg/daily | 5 (4%) | 3 (4%) | 1 (20%) |
| Oral budesonide | 4 (6%) | 4 (5%) | 0 |
| Biologics | 58 (70%) | 56 (71%) | 2 (40%) |
| Vedolizumab | 5 (6%) | 5 (6%) | 0 |
| Anti-TNF | 44 (53%) | 42 (53%) | 2 (40%) |
| Infliximab | 23 (28%) | 23 (29%) | 0 |
| Adalimumab | 21 (25%) | 19 (24%) | 2 (40%) |
| Ustekinumab | 9 (11%) | 9 (11%) | 0 |
| Tofacitinib | 4 (5%) | 4 (5%) | 0 |
| COVID-19 Characteristics | |||
| COVID-19 symptoms | |||
| Fever >99 F | 55 (66%) | 52 (66%) | 3 (60%) |
| Cough | 46 (55%) | 44 (56%) | 2 (20%) |
| Pharyngitis | 21 (25%) | 21 (27%) | 0 |
| Rhinorrhea | 15 (18%) | 15 (19%) | 0 |
| Diarrhea | 26 (31%) | 24 (30%) | 2 (40%) |
| Ageusia | 18 (22%) | 18 (23%) | 0 |
| Anosmia | 25 (30%) | 25 (32%) | 0 |
| Shortness of breath | 21 (25%) | 17 (22%) | 4 (80%) |
| Days of symptoms (median, IQR) | 11 (5–15) | 11 (6–15) | 17 (9–32) |
| Positive SARS-CoV-2 testing | 45 (54%) | 40 (51%) | 5 (100%) |
| Highly suspected COVID-19 | 38 (46%) | 39 (49%) | 0 |
| Level of care | |||
| Notified provider | 28 (34%) | 28 (36%) | - |
| Outpatient provider visit | 48 (58%) | 48 (61%) | - |
| Severe outcomes | 7 (8%) | 2 (3%) | 5 (100%) |
| ER only | 2 (2%) | 2 (3%) | - |
| Hospitalized | 5 (6%) | - | 5 (100%) |
| ICU with intubation | 1 (1%) | - | 1 (20%) |
| IBD medication management | |||
| Continued | 58 (70%) | 57 (72%) | 1 (20%) |
| Held | 13 (16%) | 10 (13%) | 3 (60%) |
| Reduced dose/frequency | 7 (8%) | 7 (9%) | 0 |
| After reduction, required holding | 3 (4%) | 3 (4%) | 0 |
| Medical therapies for COVID-19 | |||
| None | 75 (90%) | 74 (94%) | 2 (40%) |
| Any COVID-19 therapy | 8 (10%) | 5 (6%) | 3 (60%) |
| Hydroxycholorquine + Azithromycin | 4 (5%) | 2 (3%) | 2 (40%) |
| Hydroxycholorquine | 2 (2%) | 2 (3%) | 0 |
| Azithromycin | 1 (1%) | 1 (1%) | 0 |
| Hydroxycholorquine + Azithromycin + Tocilizumab | 1 (1%) | 0 | 1 (20%) |
| Death | 1 (2%) | 0 | 1 (20%) |
| Days of follow-up (median, range) | 52 (11–72) | 52 (13–72) | 47 (11–55) |
| . | Total (n = 83) . | Ambulatory (n = 78) . | Hospitalized (n = 5) . |
|---|---|---|---|
| Demographics | |||
| Age (median, IQR) | 35 (27–45) | 35 (27–44) | 49 (25–76) |
| Sex | |||
| Male | 44 (53%) | 40 (51%) | 4 (80%) |
| Female | 39 (47%) | 38 (49%) | 1 (20%) |
| Race | |||
| White | 58 (70%) | 54 (70%) | 4 (80%) |
| Black | 5 (6%) | 5 (6%) | 0 |
| Asian | 3 (4%) | 3 (4%) | 0 |
| Other | 17 (20%) | 16 (21%) | 1 (20%) |
| Ethnicity | |||
| Hispanic | 9 (11%) | 7 (9%) | 2 (40%) |
| Non-Hispanic | 74 (89%) | 71 (91%) | 3 (60%) |
| Comorbidities | |||
| Organ transplantation | 2 (2%) | 2 (3%) | 0 |
| Kidney disease | 1 (2%) | 1 (1%) | 0 |
| Pregnancy | 4 (5%) | 3 (4%) | 1 (20%) |
| Current malignancy | 1 (2%) | 0 | 1 (20%) |
| Hypertension | 3 (4%) | 3 (4%) | 0 |
| Diabetes mellitus | 1 (2%) | 1 (1%) | 0 |
| COPD | 1 (2%) | 1 (1%) | 0 |
| Asthma | 9 (11%) | 9 (12%) | 0 |
| ACE inhibitor/ARB use | 6 (7%) | 5 (6%) | 1 (20%) |
| IBD Characteristics | |||
| IBD subtype | |||
| Crohn’s disease | 56 (67%) | 52 (67%) | 4 (80%) |
| Ulcerative colitis | 27 (33%) | 26 (33%) | 1 (20%) |
| IBD disease status by physician assessment | |||
| Remission | 30 (36%) | 30 (38%) | 0 |
| Mild | 26 (31%) | 24 (31%) | 2 (40%) |
| Moderate | 14 (17%) | 13 (17%) | 1 (20%) |
| Severe | 6 (7%) | 4 (5%) | 2 (40%) |
| Unknown | 7 (8%) | 7 (9%) | 0 |
| IBD medication use | |||
| None | 4 (5%) | 3 (4%) | 1 (20%) |
| 5-ASA | 13 (16%) | 11 (14%) | 1 (20%) |
| Immunomodulators | 6 (7%) | 5 (6%) | 1 (20%) |
| Azathioprine/Mercaptopurine | 2 (2%) | 2 (3%) | 0 |
| Methotrexate | 4 (5%) | 3 (4%) | 1 (20%) |
| Corticosteroids | 10 (12%) | 8 (10%) | 1 (20%) |
| Prednisone | 6 (6%) | 4 (5%) | 1 (20%) |
| >20 mg/daily | 5 (4%) | 3 (4%) | 1 (20%) |
| Oral budesonide | 4 (6%) | 4 (5%) | 0 |
| Biologics | 58 (70%) | 56 (71%) | 2 (40%) |
| Vedolizumab | 5 (6%) | 5 (6%) | 0 |
| Anti-TNF | 44 (53%) | 42 (53%) | 2 (40%) |
| Infliximab | 23 (28%) | 23 (29%) | 0 |
| Adalimumab | 21 (25%) | 19 (24%) | 2 (40%) |
| Ustekinumab | 9 (11%) | 9 (11%) | 0 |
| Tofacitinib | 4 (5%) | 4 (5%) | 0 |
| COVID-19 Characteristics | |||
| COVID-19 symptoms | |||
| Fever >99 F | 55 (66%) | 52 (66%) | 3 (60%) |
| Cough | 46 (55%) | 44 (56%) | 2 (20%) |
| Pharyngitis | 21 (25%) | 21 (27%) | 0 |
| Rhinorrhea | 15 (18%) | 15 (19%) | 0 |
| Diarrhea | 26 (31%) | 24 (30%) | 2 (40%) |
| Ageusia | 18 (22%) | 18 (23%) | 0 |
| Anosmia | 25 (30%) | 25 (32%) | 0 |
| Shortness of breath | 21 (25%) | 17 (22%) | 4 (80%) |
| Days of symptoms (median, IQR) | 11 (5–15) | 11 (6–15) | 17 (9–32) |
| Positive SARS-CoV-2 testing | 45 (54%) | 40 (51%) | 5 (100%) |
| Highly suspected COVID-19 | 38 (46%) | 39 (49%) | 0 |
| Level of care | |||
| Notified provider | 28 (34%) | 28 (36%) | - |
| Outpatient provider visit | 48 (58%) | 48 (61%) | - |
| Severe outcomes | 7 (8%) | 2 (3%) | 5 (100%) |
| ER only | 2 (2%) | 2 (3%) | - |
| Hospitalized | 5 (6%) | - | 5 (100%) |
| ICU with intubation | 1 (1%) | - | 1 (20%) |
| IBD medication management | |||
| Continued | 58 (70%) | 57 (72%) | 1 (20%) |
| Held | 13 (16%) | 10 (13%) | 3 (60%) |
| Reduced dose/frequency | 7 (8%) | 7 (9%) | 0 |
| After reduction, required holding | 3 (4%) | 3 (4%) | 0 |
| Medical therapies for COVID-19 | |||
| None | 75 (90%) | 74 (94%) | 2 (40%) |
| Any COVID-19 therapy | 8 (10%) | 5 (6%) | 3 (60%) |
| Hydroxycholorquine + Azithromycin | 4 (5%) | 2 (3%) | 2 (40%) |
| Hydroxycholorquine | 2 (2%) | 2 (3%) | 0 |
| Azithromycin | 1 (1%) | 1 (1%) | 0 |
| Hydroxycholorquine + Azithromycin + Tocilizumab | 1 (1%) | 0 | 1 (20%) |
| Death | 1 (2%) | 0 | 1 (20%) |
| Days of follow-up (median, range) | 52 (11–72) | 52 (13–72) | 47 (11–55) |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
